Edwards Lifesciences ve 2. čtvrtletí 2026 zvýšila tržby TMTT o 44,8 % a tržby TAVR o 10,5 % při konstantních kurzech měn; výhled růstu tržeb TAVR zvýšila na 8–9 %.
Key Takeaways Edwards Lifesciences' TMTT sales surged 44.8% in Q2 2026, driven by PASCAL, EVOQUE and SAPIEN M3.EW's TAVR sales grew 10.5% on a constant-currency basis, lifting 2026 growth guidance to 8-9%.EW's $2.9 billion cash balance supports investments and buybacks, but tariffs and FX pressure margins.
Edwards Lifesciences (EW - Free Report) sees Transcatheter Mitral and Tricuspid Therapies (“TMTT”) momentum, fueled by PASCAL, EVOQUE and SAPIEN M3, supported by clinical evidence and broader market access. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) business continues to grow, with SAPIEN platform durability and evidence supporting earlier treatment of aortic stenosis. Its strong balance sheet boosts investments and share repurchases. Meanwhile, Edwards faces tariff uncertainty and adverse currency movements that could pressure margins and earnings.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 15% compared with the 2% growth of the industry and the S&P 500 composite’s 16% return.
The renowned global medical device company has a market capitalization of $43.95 billion. EW’s earnings yield of 2.7% favorably compares to the industry’s negative 2.2% yield. In the trailing four quarters, Edwards delivered an average earnings surprise of 5.7%.
Let’s delve deeper.
Upsides for EW StockTMTT Portfolio Holds Potential: Edwards’ TMTT portfolio remains a major source of growth as the company scales repair and replacement therapies across mitral and tricuspid disease. Second-quarter 2026 TMTT sales were $195.9 million, up 44.8% on a constant-currency basis, with global mitral and tricuspid procedure growth remaining in the double digits. PASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations. PASCAL adoption continues to increase, supported by differentiated design and clinical outcomes. Real-world data showed sustained one-year safety and effectiveness for PASCAL PRECISION in more than 4,600 U.S. degenerative mitral regurgitation patients.
Edwards also received CE Mark for SAPIEN M3 RESILIA and broadened the European indication for SAPIEN M3 and SAPIEN M3 RESILIA to patients with mitral annular calcification. ENCIRCLE registry data also showed low 30-day mortality, near elimination of regurgitation and quality-of-life improvement in this population. The company expects these layered platforms to provide durable growth beyond the current launch phase as access broadens and centers gain experience.
Image Source: Zacks Investment Research
TAVR Looks Promising: Edwards’ TAVR franchise continues to benefit from the clinical and technology investments built around the SAPIEN platform. Second-quarter 2026 TAVR sales were about $1.3 billion and increased 10.5% on a constant-currency basis. Growth rates were similar in the United States and outside the United States, while average selling prices remained stable globally. Edwards also reported modest year-over-year competitive position gains in the United States and Europe.
The evidence base continues to support broader and earlier treatment. A seven-year PARTNER 3 subanalysis reinforced SAPIEN valve performance and durability, while a five-year EARLY TAVR analysis added evidence supporting intervention earlier in the aortic-stenosis disease pathway. Updated European guidelines are also shaping clinical discussion around proactive treatment, and Japan approved the asymptomatic indication in second-quarter 2026.
The next catalyst is the PROGRESS trial, which will evaluate whether certain moderate aortic-stenosis patients may benefit from earlier TAVR treatment. Following second-quarter performance, management raised 2026 TAVR constant-currency sales growth guidance to 8-9% from 7-9%.
Strong Solvency: Edwards ended second-quarter 2026 with about $2.9 billion in cash and cash equivalents, with roughly $600 million of debt, providing flexibility for investment and repurchases. About $1.5 billion remained under its repurchase authorization.
What Ails Edwards?Macro Concerns Weigh on Margins: Edwards’ global manufacturing and commercial footprint leaves results exposed to trade-policy changes, inflation and cross-border cost shifts. In its second-quarter 2026 filing, the company said increased U.S. tariffs and retaliatory tariffs could affect its business and that it is evaluating supply-chain, exemption and exclusion options to mitigate potential effects. The company cannot predict future tariff rates or whether mitigation will be sufficient. Current results also show sensitivity to external cost factors. Adjusted gross margin was 77.6% in second-quarter 2026, flat year over year, as lower manufacturing expenses offset foreign-exchange effects.
Foreign Exchange Remains a Margin Risk: Currency movements remain an important earnings variable because Edwards generates substantial sales and expenses outside the United States. Foreign exchange increased second-quarter 2026 reported sales by about $15 million but reduced adjusted gross margin by roughly 70 basis points versus the prior year. Management expects foreign exchange to reduce second-half sales by about $35 million if rates remain at current levels and now sees 2026 gross margin near the lower end of its 78%-79% range.
EW Stock Estimate TrendThe Zacks Consensus Estimate for Edwards’ 2026 earnings per share (EPS) has remained constant at $3.00 in the past 60 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $6.76 billion, suggesting an 11.4% improvement from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7%. Shares of the company have dropped 2.3% compared with the industry’s 26.8% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.7% against the industry’s negative 2.2% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. IDXX shares have plunged 12.7% against the industry’s 2% growth over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 26.1% compared with the industry’s 2% gain over the past year.
First Citizens Bank & Trust Co. bought a new stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,174 shares of the medical research company’s stock, valued at approximately $792,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $1,274,082,000. Bank of America Corp DE purchased a new position in Edwards Lifesciences in the second quarter valued at about $605,397,000. Deutsche Bank AG purchased a new position in Edwards Lifesciences in the second quarter valued at about $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Edwards Lifesciences by 0.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after purchasing an additional 30,495 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.
Insider Activity In other news, VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth A number of brokerages have commented on EW. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Evercore reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. UBS Group reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Thursday, October 8th. Mizuho boosted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.27. View Our Latest Analysis on Edwards Lifesciences
Edwards Lifesciences Price Performance EW opened at $86.52 on Friday. The company has a fifty day simple moving average of $88.44 and a 200 day simple moving average of $86.33. The firm has a market cap of $49.82 billion, a price-to-earnings ratio of 49.72, a PEG ratio of 2.31 and a beta of 0.87. Edwards Lifesciences Corporation has a twelve month low of $72.67 and a twelve month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the business posted $0.67 EPS. The firm’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3.00 EPS for the current fiscal year.
Edwards Lifesciences Profile (Free Report)
Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.
Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.
See Also Five stocks we like better than Edwards Lifesciences Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Edwards Lifesciences očekává, že TMTT by měl v roce 2026 přinést zhruba 250 milionů USD tržeb a růst asi o 40 %. Firma dál míří na více než 2 miliardy USD tržeb z TMTT do roku 2030.
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.
Zovighian said the company’s focus on structural heart disease provides “strategic clarity” in a large and growing market with significant unmet patient need. He said Edwards’ approximately 17,000 employees are driven by the company’s patient-focused mission, while its leadership team is concentrated on execution in structural heart disease.
Get Edwards Lifesciences alerts:
CMS Coverage Decision Expands TAVR Flexibility Beyond Biotech—3 Healthcare Stocks for Growth-Minded InvestorsA central topic of the discussion was the recent Centers for Medicare & Medicaid Services National Coverage Determination, or NCD, for TAVR. Zovighian characterized the decision as positive for patients, the field and Edwards, saying CMS determined that the therapy is “reasonable and necessary” following years of clinical evidence and physician experience.
He identified four major elements of the updated policy:
Greater flexibility in patient evaluation, including one required in-person physician visit rather than two. Greater flexibility during procedures, with one required operator rather than a mandatory surgeon and cardiologist both present in the room. Removal of hospital procedure-volume requirements to establish a TAVR program, while operator requirements remain in place. Coverage with evidence development for asymptomatic patients and a pathway for Medicare Administrative Contractor coverage of future FDA-approved indications. 3 Healthcare Pathbreakers With Long-Term TailwindsEdwards estimates there are roughly 1,100 cardiac surgery centers in the U.S., compared with about 850 existing TAVR centers. Zovighian said the gap represents a potential opportunity for some cardiac surgery centers to open TAVR programs, though he does not expect all of them to do so. He estimated that perhaps 100 to 200 new centers could ultimately open, with adoption occurring over time as hospitals make decisions, receive approvals and train staff.
Chief Financial Officer Doretta Mistras said the coverage changes create multi-year opportunities rather than a near-term surge followed by a decline. She said the company continues to expect durable TAVR growth in the mid- to high-single-digit range.
Moderate Aortic Stenosis Trial Nears Results Zovighian also discussed the company’s PROGRESS trial in moderate aortic stenosis, with results expected in approximately six weeks at the TCT meeting. He declined to speculate about potential outcomes or the market implications of different trial results.
He said Edwards launched the study based on its belief that treating aortic stenosis patients earlier, before further disease progression, could be beneficial. The study enrolled quickly, which he described as an encouraging sign of physician interest. However, he emphasized that the trial evaluates only the most severe moderate patients with at least one risk factor.
While acknowledging the potential size of the moderate patient population, Zovighian said it is difficult to precisely estimate the total addressable market before patients are broadly identified and treated. Mistras added that penetration in Edwards’ existing market remains in the low teens, leaving meaningful opportunity even without additional indications.
TMTT Portfolio Targets Further Growth For transcatheter mitral and tricuspid therapies, or TMTT, Zovighian said Edwards is focused on PASCAL for mitral regurgitation, PASCAL for tricuspid regurgitation, EVOQUE and SAPIEN M3. He said the business is on track for roughly $250 million in revenue and approximately 40% growth in 2026.
The company remains focused on its previously stated goal of more than $2 billion in TMTT revenue by 2030, though Zovighian said Edwards’ longer-term ambition is broader than that target. He cited millions of patients with mitral and tricuspid disease who lack treatment options.
Edwards expects a PASCAL tricuspid approval before year-end, which Zovighian said would add an incremental growth opportunity. EVOQUE is expanding through both new-center openings and increased utilization at existing centers, while SAPIEN M3 is in the early stages of its commercial launch following approval earlier this year, he said.
On tricuspid disease, Zovighian said the category remains early in its development because physicians had few options until recently. He pointed to the TRIC-I-HF study from German centers as evidence of progress in the field’s understanding, noting that the study showed a mortality benefit in addition to quality-of-life benefits.
Capital Allocation and Long-Term Focus Mistras said Edwards’ first capital-allocation priority is investment in internal capabilities, including its manufacturing network. The company also plans to evaluate external opportunities that fit its structural-heart strategy and allow Edwards to participate early in development. As a third priority, she said Edwards will continue to repurchase shares opportunistically, noting that it had bought back more than $500 million of stock year to date.
Zovighian said the company’s long-term target is to grow revenue by about 10%, supported by catalysts across its five therapy areas. He also said artificial intelligence could increasingly help hospitals improve disease awareness, imaging analysis, diagnostics and treatment decisions over the coming years.
About Edwards Lifesciences (NYSE:EW)Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.
The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Edwards Lifesciences Right Now?Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Bank of Nova Scotia ve 2. čtvrtletí otevřela novou pozici v Edwards Lifesciences za zhruba 5,465 milionu USD. Firma zároveň oznámila EPS 0,78 USD a tržby 1,74 miliardy USD, obojí nad odhady.
Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company’s stock, valued at approximately $5,465,000.
Several other hedge funds also recently made changes to their positions in EW. BlackRock Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences in the second quarter worth about $1,274,082,000. Norges Bank bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $803,686,000. Deutsche Bank AG bought a new position in shares of Edwards Lifesciences in the second quarter worth about $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.
Edwards Lifesciences Stock Up 0.5% Shares of EW opened at $90.92 on Wednesday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a market cap of $52.35 billion, a PE ratio of 52.25, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $89.35 and a 200 day moving average of $84.82.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year. Insider Transactions at Edwards Lifesciences In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 2,425 shares of company stock valued at $219,199. 0.31% of the stock is owned by insiders.
Analyst Ratings Changes A number of research analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Evercore reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Citigroup increased their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $100.27.
Read Our Latest Stock Report on Edwards Lifesciences
(Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
See Also Five stocks we like better than Edwards Lifesciences Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 37,702 shares of the medical research company’s stock, valued at approximately $3,410,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $5,318,092,000. State Street Corp increased its holdings in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after buying an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences during the second quarter valued at about $1,274,082,000. Finally, Norges Bank bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Edwards Lifesciences Stock Up 0.1% Shares of NYSE:EW opened at $89.89 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company’s 50-day moving average price is $89.21 and its two-hundred day moving average price is $84.67. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $51.76 billion, a P/E ratio of 51.66, a P/E/G ratio of 2.26 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year. Wall Street Analysts Forecast Growth EW has been the topic of several recent research reports. BTIG Research lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Truist Financial raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, Evercore reissued an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.
View Our Latest Stock Analysis on Edwards Lifesciences
Insider Buying and Selling at Edwards Lifesciences In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by company insiders.
(Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles Five stocks we like better than Edwards Lifesciences 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Edwards Lifesciences zvýšil ve 2. čtvrtletí tržby TMTT o 44,8 % a TAVR o 10,5 % při konstantním kurzu. Firma ale čeká, že kurzové vlivy sníží tržby v druhém pololetí asi o 35 milionů USD.
Key Takeaways Edwards Lifesciences' TMTT sales rose 44.8%, while TAVR sales increased 10.5% at constant currency. EW's TAVR growth is supported by SAPIEN investments, clinical evidence and broader treatment opportunities. Edwards Lifesciences expects FX to cut second-half sales by about $35 million if current rates persist. Edwards Lifesciences’ (EW - Free Report) Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business has seen consistent growth over the past few quarters, which is highly encouraging. The company’s TAVR platform represents another significant growth opportunity, supported by patient activation and advanced new technologies. However, ongoing currency swings and intense competition could weigh on Edwards’ financial results.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 16.9% against the 6.5% decline of the industry. The S&P 500 composite rose 22.3% at the same time.
The renowned global medical device company has a market capitalization of $49.51 billion. EW’s earnings yield of 3.3% favorably compares with the industry’s negative 1.6% yield. In the trailing four quarters, Edwards delivered an average earnings surprise of 4.5%.
Let’s delve deeper.
Upsides for EW StockTAVR Holds Potential: Edwards’ TAVR franchise continues to benefit from the clinical and technology investments built around the SAPIEN platform. Second-quarter 2026 TAVR sales were about $1.3 billion and increased 10.5% on a constant-currency basis. The evidence base continues to support broader and earlier treatment. A seven-year PARTNER 3 subanalysis reinforced SAPIEN valve performance and durability, while a five-year EARLY TAVR analysis added evidence supporting intervention earlier in the aortic-stenosis disease pathway.
Updated European guidelines are also shaping clinical discussion around proactive treatment, and Japan approved the asymptomatic indication in second-quarter 2026. The next catalyst is the PROGRESS trial, which will evaluate whether certain moderate aortic-stenosis patients may benefit from earlier TAVR treatment.
TMTT Portfolio Holds Potential: Edwards’ TMTT portfolio remains a major source of growth as it scales repair and replacement therapies across mitral and tricuspid disease. Second-quarter 2026 TMTT sales were $195.9 million, up 44.8% on a constant-currency basis, with global mitral and tricuspid procedure growth remaining in the double digits. PASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations.
During second-quarter 2026, Edwards received CE Mark for SAPIEN M3 RESILIA and broadened the European indication for SAPIEN M3 and SAPIEN M3 RESILIA to patients with mitral annular calcification. ENCIRCLE registry data also showed low 30-day mortality, near elimination of regurgitation and quality-of-life improvement in this population.
Image Source: Zacks Investment Research
What Ails EW Stock?Foreign Exchange Remains a Margin Risk: Currency movements remain an important earnings variable because Edwards generates substantial sales and expenses outside the United States. Foreign exchange increased second-quarter 2026 reported sales by about $15 million, but reduced adjusted gross margin by roughly 70 basis points compared with the prior year. Management expects foreign exchange to reduce second-half sales by about $35 million if rates remain at current levels and now sees 2026 gross margin near the lower end of its 78% to 79% range.
Competitive Landscape Remains Intense: Structural heart remains a highly competitive medical-technology market, requiring continued investment in evidence, product development and physician adoption. Edwards reported modest year-over-year competitive-position gains in U.S. and European TAVR during second-quarter 2026, but part of growth still reflected a competitor’s 2025 market exit, with management indicating the European benefit was likely ending after the quarter. The company, therefore, must sustain SAPIEN differentiation as that comparison rolls off. Edwards is investing in next-generation SAPIEN and PASCAL technologies, yet failure to maintain technological or evidence advantages could weaken share and raise commercial spending over time.
EW Stock Estimate TrendThe Zacks Consensus Estimate for Edwards’ 2026 earnings per share (EPS) has remained constant at $3.00 in the past 30 days.
The consensus estimate for its 2026 revenues is pegged at $6.76 billion, indicating an 11.4% improvement from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% in contrast to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% compared to the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% rise. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.
BlackRock Inc. bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 58,789,433 shares of the medical research company’s stock, valued at approximately $5,318,092,000. BlackRock Inc. owned approximately 10.21% of Edwards Lifesciences at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.
Edwards Lifesciences Stock Up 0.4% Shares of NYSE EW opened at $91.13 on Wednesday. The stock has a market capitalization of $52.47 billion, a price-to-earnings ratio of 52.37, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The firm has a 50-day moving average price of $88.90 and a 200 day moving average price of $84.49. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year. Insider Buying and Selling In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth A number of research analysts recently issued reports on the company. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Evercore restated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. UBS Group assumed coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.
Read Our Latest Research Report on EW
Edwards Lifesciences Company Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More Five stocks we like better than Edwards Lifesciences The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Akcie Edwards Lifesciences za tři měsíce vzrostly o 14 %, tažené silným růstem TAVR a TMTT. Firma zároveň zvýšila výhled tržeb TMTT na rok 2026 na 760–780 milionů USD.
Key Takeaways Edwards gained 14% in three months as TAVR and TMTT growth strengthened its operating case. TMTT sales rose 44.8% at constant currency, prompting Edwards to raise its 2026 sales outlook. FX, litigation, reimbursement and competition remain risks as Edwards trades at 28.8X forward EPS. Edwards Lifesciences Corporation (EW - Free Report) shares have gained 14% in the past three months as growth across its structural-heart franchises has strengthened the operating case. Second-quarter results showed double-digit expansion in transcatheter aortic valve replacement and faster growth in transcatheter mitral and tricuspid therapies.
The rally leaves investors balancing broader growth and raised 2026 expectations against a valuation that already reflects meaningful execution.
EW’s 3-Month Gain Meets a Premium ValuationEW trades at 28.8X forward 12-month EPS, above 27.3X for the Zacks sub-industry and 20.7X for the S&P 500. The stock has also outpaced the S&P 500’s 4.5% gain over the past three months, although it trails the sub-industry’s 18.9% advance.
Image Source: Zacks Investment Research
The current multiple is close to Edwards’ five-year median of 30.0X. That positioning suggests the market is already assigning substantial value to continued growth, leaving less room for execution setbacks after the recent share-price increase.
Edwards’ Growth Engines Remain Broad-BasedSecond-quarter 2026 TAVR sales reached $1.26 billion, rising 10.5% at constant currency. TMTT sales increased 44.8% at constant currency to $195.9 million, while Surgical sales advanced 5% at constant currency to $284 million.
The mix matters because Edwards is not relying on a single franchise. TAVR remains the largest platform, Surgical continues to benefit from RESILIA-based technologies and TMTT is adding a faster-growth layer. Medtronic plc (MDT - Free Report) remains a relevant structural-heart competitor, with its Evolut TAVR platform supported by ongoing clinical evidence.
EW’s TMTT Momentum Adds a Faster-Growth LayerPASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations in the second quarter. PASCAL adoption increased, EVOQUE expanded through new and existing centers, and SAPIEN M3 broadened Edwards’ mitral replacement offering.
Management raised its 2026 TMTT sales outlook to $760-$780 million from $740-$780 million and continues to target $2 billion in TMTT revenues by 2030. That target highlights the franchise’s role in Edwards’ longer-term growth plan as access broadens and treatment centers gain experience.
Edwards Faces FX, Litigation and Coverage RisksForeign exchange reduced adjusted gross margin by about 70 basis points in the second quarter, even as it added roughly $15 million to reported sales. Management expects foreign exchange to reduce second-half sales by about $35 million if rates remain at current levels and sees 2026 gross margin near the lower end of its 78-79% range.
Per the Zacks Consensus Estimates, the company’s 2026 earnings and revenues are pegged at $3.00 and $6.76 billion, respectively.
Image Source: Zacks Investment Research
Litigation also remains unresolved, while reimbursement and trade policy could affect demand, access and costs. Management expects a final U.S. TAVR coverage decision in September 2026. Boston Scientific Corporation (BSX - Free Report) is also pursuing a potential entry into balloon-expandable TAVR through its 2026 investment in MiRus, underscoring the competitive intensity surrounding structural-heart therapies.
EW’s Mixed Signals Temper the Rally CaseEdwards’ growth profile remains favorable, but the recent advance and premium valuation make further gains more dependent on execution. Continued TAVR expansion, TMTT scaling and supportive coverage developments could help the operating case, while currency, legal and competitive risks may pressure returns.
EW currently carries a Zacks Rank #3 (Hold) and a VGM Score of C. Its Growth Score of A supports the company’s growth characteristics, while the Value Score of D and Momentum Score of F are less favorable. Together, those signals argue for selectivity after the three-month rally rather than an aggressive stance based on price performance alone.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences překonal odhady ve 2. čtvrtletí díky silné poptávce po srdečních chlopních. Tržby činily 1,74 miliardy USD a akcie v prodlouženém obchodování vzrostly téměř o 7 %.
CompaniesJuly 23 (Reuters) - Edwards Lifesciences (EW.N), opens new tab beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.
Medical technology firms are seeing increased demand for surgical and procedural devices as population ages and healthcare needs grow.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Here are some details:
Sales of Edwards' transcatheter aortic valve replacement device (TAVR) rose 11.3% over the year earlier to $1.26 billion during the quarter. Analysts on average estimated $1.23 billion, according to data compiled by LSEG.
TAVR is used to treat severe aortic stenosis, a condition where the aortic valve narrows and restricts blood flow from the heart.
Edwards raised the lower end of 2026 sales growth forecast for TAVR devices to 8% from 7% earlier, while keeping the upper end intact at 9%.
The company maintained annual adjusted profit expectations in the range of $2.95 to $3.05 per share.
The California-based company reported quarterly revenue of $1.74 billion, while analysts estimated $1.70 billion.
On an adjusted basis, Edwards earned 78 cents per share, compared with the estimate of 74 cents.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Key Takeaways EW is set to report Q2 2026 results on July 23, with revenues expected to rise 10.9% year over year.Edwards' TAVR growth may be aided by SAPIEN demand, clinical evidence and European guideline support.Edwards' TMTT and Surgical may have benefited from EVOQUE, SAPIEN M3, PASCAL and RESILIA therapy demand. Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report second-quarter 2026 results on July 23, after the market closes.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 78 cents beat the Zacks Consensus Estimate by 4%. Its earnings topped estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.79%.
Edwards' Q2 EstimatesThe Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $1.70 billion, suggesting 10.9% growth from the year-ago reported figure.
The Zacks Consensus Estimate for second-quarter 2026 net earnings of 73 cents per share indicates a 9% increase from the year-ago reported figure. The estimate has remained unchanged in the past 60 days.
Factors Likely to Influence EW’s Q2 ResultsTranscatheter Aortic Valve Replacement (TAVR)In the second quarter of 2026, the TAVR segment is likely to have maintained its momentum, aided by procedural growth amid a heightened clinical focus on proactive disease management of severe aortic stenosis. Long-term clinical evidence supporting the SAPIEN platform’s durability and valve performance may have been a key driver.
Edwards may have continued to see strong sales of the SAPIEN 3 Ultra RESILIA valve across the United States and international markets, including Japan. In Europe, continued commercial execution and sustained physician demand for the SAPIEN platform are expected to have supported performance. The company may have continued to benefit from the exit of a competitor in the prior year.
Updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic Surgery, endorsing the role of TAVR for a broader patient population, may have positively influenced the segment’s performance.
The Zacks Consensus Estimate expects TAVR revenues to grow 9.1% year over year in the second quarter.
Transcatheter Mitral and Tricuspid Therapies (TMTT)Within TMTT, Edwards’ ongoing strength in the portfolio of repair and replacement therapies to treat mitral and tricuspid diseases is expected to have resulted in solid top-line growth. The EVOQUE tricuspid valve replacement system is likely to have continued to gain traction in both the United States and Europe.
Last year, the FDA approval of the SAPIEN M3 mitral valve replacement system marked a major milestone as the first transcatheter therapy utilizing a transseptal approach. Edwards’ early commercial experience has reflected the need for this mitral replacement solution for patients for whom mitral TEER is not an appropriate treatment option.
Favorable physician feedback on patient outcomes and procedural experience is likely to have continued to support the system’s adoption in the second quarter. Demand for the PASCAL transcatheter edge-to-edge repair system may have continued to expand, driven by physician interest in its differentiated design and clinical outcomes, as well as the significant unmet need among these patients.
The Zacks Consensus Estimate expects TMTT revenues to grow 39.3% year over year in second-quarter 2026.
Surgical Structural HeartThe segment’s second-quarter performance is likely to have benefited from the continued demand for Edwards’ RESILIA therapies. The global adoption of the INSPIRIS aortic valve is expected to have remained strong, while the KONECT tissue valved conduit is likely to have continued to gain traction following its European launch. The rollout of the MITRIS valve across more international markets may have supported growth in surgical mitral valve replacement procedures.
With Edwards maintaining its outlook for mid-single-digit Surgical sales growth in 2026, the second quarter is likely to have seen continued progress toward that target.
The Zacks Consensus Estimate anticipates Surgical revenues to grow 4.1% year over year.
Earnings Whispers for EdwardsPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Labcorp (LH - Free Report) has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on July 30.
LH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%. The Zacks Consensus Estimate expects the company’s second-quarter EPS to increase 10.1% from the year-ago quarter’s figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2. The company is expected to release second-quarter 2026 results soon.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.74%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for a rise of 10.9% from the year-ago quarter’s figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 10.
ALC’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.66%. The Zacks Consensus Estimate anticipates the company’s second-quarter EPS to increase 1.3% from the year-ago quarter’s figure.
Edwards Lifesciences na konferenci New York Valves 2026 představila nová data podporující její vedení v oblasti strukturální kardiologie. Studie PROGRESS, PARTNER 3, EARLY TAVR i registry PASCAL a SAPIEN M3 posilují důkazy pro platformu SAPIEN.
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
Ahead of the planned full clinical presentation at TCT later this year, the baseline characteristics of the PROGRESS trial presented today provide new insights into the heterogeneous nature of moderate aortic stenosis (AS) patients. Research has shown that approximately half of moderate AS patients present with at least one at-risk feature, which includes symptoms, progressive cardiac damage, declining health and elevated risk of hospitalization. The PROGRESS trial is designed to evaluate whether patients with moderate AS and at least one risk factor may benefit from transcatheter aortic valve replacement (TAVR) earlier than current guidelines, which recommend clinical surveillance with echocardiographic follow-up every 1-2 years. Details of the PROGRESS trial design were recently published in the American Heart Journal and baseline characteristics of the PROGRESS trial are listed below:
More than 95% were symptomatic More than 70% had 2 or more at-risk features More than 90% had a normal left ventricular function Mean age was 78 ± 6 years Mean KCCQ score was 64 ± 24 Broad surgical risk distribution (46% low risk) Additional late-breaking clinical science presentations strengthen the evidence base for the SAPIEN 3 platform, including seven-year benchmark durability data from the PARTNER 3 trial, simultaneously published in JAMA Cardiology. Also presented were new findings from the EARLY TAVR trial, reinforcing the shift toward proactive disease management and providing continued long-term reassurance for physicians and patients. These data on Edwards’ SAPIEN platform underscore the benchmark valve performance and differentiated long-term durability of the therapy.
“Edwards remains focused on addressing the significant unmet needs of the many structural heart patients who remain untreated today,” said Bernard Zovighian, Edwards’ CEO. “Our expanding evidence base reflects Edwards’ clear and sustained commitment to advancing care through partnership with the physician community. From building a deeper understanding of the moderate AS population and advancing evidence about asymptomatic patients to demonstrating distinguished SAPIEN platform durability and strategies for lifetime disease management, we are strengthening confidence in long-term outcomes and increasing access for patients worldwide.”
Also at the meeting, new data highlighted clinical trial and real-world outcomes across Edwards’ mitral and tricuspid portfolio. Data from more than 4,500 patients treated with the PASCAL system in the STS/ACC Transcatheter Valve Therapy Registry helps highlight the sustained safety and effectiveness of the technology for patients with mitral regurgitation (MR). One-year data from the ENCIRCLE trial Mitral Annular Calcification (MAC) Registry support the safety, effectiveness and quality of life improvements with SAPIEN M3, the first and only transcatheter transseptal mitral valve replacement system, in patients with symptomatic valve dysfunction associated with MAC who are deemed unsuitable for surgery or TEER therapy by a heart team.
Zovighian added, “Together, our differentiated technology and world-class evidence reflect Edwards’ leadership in elevating the standard of care for structural heart patients and improving outcomes across the care continuum.”
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian and statements regarding the benchmark performance and differentiated long-term durability of Edwards’ SAPIEN platform, elevating the standard of care, our leadership in advancing our growing body of high-quality scientific and clinical evidence, long-term reassurance for physicians and patients, our commitment to advance care through partnerships with the physician community, strengthen confidence in long-term outcomes and expanding access for patients, innovating for patients with structural heart disease, the safety and effectiveness and quality of life improvements of our products, and improving outcomes across the care continuum, and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, ENCIRCLE, PARTNER, PARTNER 3, PASCAL, PROGRESS, SAPIEN, SAPIEN 3 and SAPIEN M3 are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
